SINGAPORE, 19 April 2022 – MGI, a company committed to being a world-leading life science innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low-coverage whole genome sequencing for risk prediction and pharmacogenomics. The collaboration will optimise Next Generation Sequencing (NGS) workflows using MGI’s sequencing devices and products*.
The partnership aims to leverage NALA’s Clinical Decision Support, a software medical device, to analyse whole genome sequencing data generated by MGI’s DNBSEQ™ platform* and produce clinical-grade reports for pharmacogenomics and polygenic risk scores. While NGS captures extensive genomic information for tailored clinical management and treatment, its workflows are complex and challenging to implement in clinical settings. NALA brings expertise in pharmacogenetics, assay development, and AI-powered genetics analysis to facilitate clinical genetic testing in Southeast Asia.
“Pharmacogenetic testing adoption in Southeast Asia remains low despite growing interest, as NGS involves multi-step processes that are difficult to implement,” said Dr Roy Tan, General Manager, MGI Asia Pacific. “Our partnership with Nalagenetics combines our expertise to simplify the NGS workflow with automation, sequencing primer design, and process QC within existing healthcare frameworks.”
“We see increasing adoption of sequencing in hospitals for personalised medicine in oncology, cardiovascular conditions, and more. One key challenge is recommending follow-up actions suited to the local market, such as alternative therapies and cost-effective screening procedures. We are delighted to work with MGI to co-develop products and services that address local needs,” said Levana Sani, CEO of Nalagenetics.
About Nalagenetics
Nalagenetics is a biotechnology company specialising in personalised screening and intervention. It aims to provide affordable, actionable genetic testing relevant to local populations through partnerships with hospitals and laboratories. Its main product, Clinical Decision Support, allows providers to generate clinical-grade genetic reports from raw genetic data and clinical input. Nalagenetics has a presence in Southeast Asia and Europe. For more information, visit nalagenetics.com.
